Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)

NCT04994717 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04994717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04994717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 2, 2021
Completion date
June 30, 2031
Enrollment
303 (actual)
Sites
192

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed philadelphia (ph)-negative b-cell precursor acute lymphoblastic leukemia (all)